Thilo joined Kimia Therapeutics as Vice President of Medicinal Chemistry in November 2023, bringing over 18 years of experience and a proven track record of successfully moving drug candidates from the laboratory to clinical trials. He is a highly accomplished medicinal chemist with over 80 scientific publications and patents.

‍

At Kimia, Thilo leads the advancement of promising compounds identified by the company's ATLAS platform through lead optimization and pre-clinical development.

‍

Prior to Kimia, Thilo held leadership positions at several prominent biotechnology companies:

‍

• PTC Therapeutics: As Executive Director and Site Head of Chemistry, he oversaw internal and external chemistry teams, driving drug discovery efforts in neurology and oncology.

‍

• Assembly Biosciences: As Director of Medicinal Chemistry, he contributed to the development of novel treatments for chronic Hepatitis B and discovered the capsid inhibitor ABI-4334 currently in Phase I clinical trials.

‍

• Rigel Pharmaceuticals: Over 13 years, Thilo progressed through roles of increasing responsibility, advancing multiple kinase inhibitor programs for immunology and oncology into clinical development. These programs included notable drug candidates like Bemcentinib (AXL inhibitor), R835 (IRAK4 inhibitor), R548 (JAK3 inhibitor), and AZD0449 (IL-13/IL-4 signaling inhibitor).

‍

Thilo holds a Ph.D. in Organic Chemistry from the University of Vienna and completed his post-doctoral training at UC Berkeley. His academic achievements include prestigious fellowships from the Kekulé and Alexander von Humboldt Foundations.

‍